文献速递冠心病血脂与心血管预防

普拉格雷与替格瑞洛在急性心肌梗死直接PCI后1年结局比较

1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor.
PubMed 文献 · J Am Coll Cardiol · 2017-11-14

PRAGUE-18研究1年随访显示,急性心肌梗死直接PCI患者中,普拉格雷与替格瑞洛在心血管死亡、心梗或卒中复合终点及主要出血方面均无显著差异;因经济原因出院后早期换用氯吡格雷未增加缺血事件风险。

要点

  • 普拉格雷与替格瑞洛1年疗效与安全性相似,复合终点及出血事件无显著差异。
  • 因经济原因早期换用氯吡格雷者未增加主要心血管事件风险。
  • 换药组缺血风险本身较低,解读换药安全性需考虑混杂因素。

核心结论

  • 普拉格雷与替格瑞洛在急性心肌梗死直接PCI后1年内疗效相似。
  • 因经济原因出院后早期换用氯吡格雷未与缺血事件风险增加相关。

研究设计与样本

  • PRAGUE-18研究为随机对照试验,共纳入1230例接受直接PCI的急性心肌梗死患者。
  • 患者随机接受普拉格雷或替格瑞洛,计划治疗12个月,随访1年。

主要发现

  • 1年复合终点(心血管死亡、心梗或卒中)发生率普拉格雷组6.6%,替格瑞洛组5.7%(HR 1.167;95%CI 0.742-1.835;p=0.503)。
  • 心血管死亡3.3% vs 3.0%(p=0.769),心梗3.0% vs 2.5%(p=0.611),卒中1.1% vs 0.7%(p=0.423)。
  • 全因死亡4.7% vs 4.2%(p=0.654),明确支架血栓1.1% vs 1.5%(p=0.535)。
  • 所有出血10.9% vs 11.1%(p=0.999),TIMI大出血0.9% vs 0.7%(p=0.754)。
  • 因经济原因换用氯吡格雷者普拉格雷组34.1%(n=216),替格瑞洛组44.4%(n=265)(p=0.003)。

关键数值与推荐

  • 复合终点为1年心血管死亡、心肌梗死或卒中。
  • 换用氯吡格雷者主要心血管事件风险较低,但其缺血风险也较低。

临床怎么用

  • 急性心肌梗死直接PCI后选择普拉格雷或替格瑞洛均可,1年疗效与安全性相当。
  • 因经济原因早期换用氯吡格雷在本研究中未显示增加缺血风险,但需个体化评估。

局限性

  • 原文摘要未系统报告研究局限性。
  • 换用氯吡格雷非随机分配,组间缺血风险基线不同,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early outcomes of patients in the PRAGUE-18 (Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction) study did not find any significant differences between 2 potent P2Y12 inhibitors. OBJECTIVES: The 1-year follow-up of the PRAGUE-18 study focused on: 1) a comparison of efficacy and safety between prasugrel and ticagrelor; and 2) the risk of major ischemic events related to an economically motivated post-discharge switch to clopidogrel. METHODS: A total of 1,230 patients with acute myocardial infarction (MI) treated with primary percutaneous coronary intervention were randomized to prasugrel or ticagrelor with an intended treatment duration of 12 months. The combined endpoint was cardiovascular death, MI, or stroke at 1 year. Because patients had to cover the costs of study medication after hospital discharge, some patients decided to switch to clopidogrel. RESULTS: The endpoint occurred in 6.6% of prasugrel patients and in 5.7% of ticagrelor patients (hazard ratio: 1.167; 95% confidence interval: 0.742 to 1.835; p = 0.503). No significant differences were found in: cardiovascular death (3.3% vs. 3.0%; p = 0.769), MI (3.0% vs. 2.5%; p = 0.611), stroke (1.1% vs. 0.7%; p = 0.423), all-cause death (4.7% vs. 4.2%; p = 0.654), definite stent thrombosis (1.1% vs. 1.5%; p = 0.535), all bleeding (10.9% vs. 11.1%; p = 0.999), and TIMI (Thrombolysis In Myocardial Infarction) major bleeding (0.9% vs. 0.7%; p = 0.754). The percentage of patients who switched to clopidogrel for economic reasons was 34.1% (n = 216) for prasugrel and 44.4% (n = 265) for ticagrelor (p = 0.003). Patients who were economically motivated to switch to clopidogrel had (compared with patients who continued the study medications) a lower risk of major cardiovascular events; however, they also had lower ischemic risk. CONCLUSIONS: Prasugrel and ticagrelor are similarly effective during the first year after MI. Economically motivated early post-discharge switches to clopidogrel were not associated with an increased risk of ischemic events. (Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction [PRAGUE-18]; NCT02808767).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Motovska Z, Hlinomaz O, Kala P, et al. 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor. J Am Coll Cardiol. 2017. PMID: 29154813. doi:10.1016/j.jacc.2017.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。